Bromoethane

Bromoethane

SCHEMBL43961

CCBr.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.67
CYP3A4 P08684 1/20 0.67
ESR1 P03372 4/20 0.50
ESR2 Q92731 4/20 0.50
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 2/20 0.39
TP53 P04637 1/20 0.39
TRPA1 O75762 1/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
KCNN4 O15554 1/20 0.36
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
DRD1 P21728 3/20 0.34
PSIP1 O75475 1/20 0.33
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Propyl Bromide SCHEMBL1400032 0.90 TDP1 (0.60) TDP1CYP3A4ESR1ESR2KDM4E
Propane SCHEMBL28233649 0.88 CYP3A4 (0.75) TDP1CYP3A4ESR1ESR2KDM4E
Dibromomethane SCHEMBL7950072 0.88 TDP1 (0.75) TDP1CYP3A4ESR1ESR2KDM4E
Dibromomethane SCHEMBL5329477 0.88 TDP1 (0.75) TDP1CYP3A4ESR1ESR2KDM4E
Propane SCHEMBL27796760 0.88 CYP3A4 (0.75) TDP1CYP3A4ESR1ESR2KDM4E
Butane SCHEMBL27989459 0.86 CYP3A4 (0.71) TDP1CYP3A4ESR1ESR2KDM4E
1,2-Dibromoethane SCHEMBL28837174 0.86 TDP1 (0.71) TDP1CYP3A4ESR1ESR2KDM4E
Butane SCHEMBL28244852 0.86 CYP3A4 (0.71) TDP1CYP3A4ESR1ESR2KDM4E
Bromomethane SCHEMBL28892441 0.85 TDP1 (0.80) TDP1CYP3A4ESR1ESR2KDM4E
Bromomethane SCHEMBL3346 0.85 TDP1 (0.80) TDP1CYP3A4ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154401-A1 REDUCED-POLYMER-LOADING, HIGH-TEMPERATURE FRACTURING FLUIDS AND METHODS AND SYSTEMS RELATED THERETO SAUDI ARABIAN OIL COMPANY (SA) 2025-05-15 US claimed
US-12209218-B2 Reduced-polymer-loading, high-temperature fracturing fluids and methods and systems related thereto SAUDI ARABIAN OIL COMPANY (SA) 2025-01-28 US claimed
WO-2024263632-A1 REDUCED-POLYMER-LOADING, HIGH-TEMPERATURE FRACTURING FLUIDS AND METHODS AND SYSTEMS RELATED THERETO SAUDI ARABIAN OIL COMPANY (SA) 2024-12-26 WO claimed
US-20240425748-A1 REDUCED-POLYMER-LOADING, HIGH-TEMPERATURE FRACTURING FLUIDS AND METHODS AND SYSTEMS RELATED THERETO SAUDI ARABIAN OIL COMPANY (SA) 2024-12-26 US claimed
CN-221460264-U Propyl dicyclohexyl pentene monomer production line 江苏广域化学有限公司 2024-08-02 CN claimed
CN-221084682-U Methyl diphenyl pentene liquid crystal monomer production line 江苏广域化学有限公司 2024-06-07 CN claimed
CN-117487141-A Polyester resin containing cyclopropyl main chain structure, powder coating and preparation method thereof 江苏达美瑞新材料有限公司 2024-02-02 CN claimed
CN-116199870-B Polyester resin containing isobutyl side group structure, powder coating and preparation method thereof 江苏达美瑞新材料有限公司 2024-01-26 CN claimed
CN-116987323-B Composite material, polyester resin, and preparation method and application thereof 广东腐蚀科学与技术创新研究院 2023-12-26 CN claimed
CN-116987323-A Composite material, polyester resin, and preparation method and application thereof 广东腐蚀科学与技术创新研究院 2023-11-03 CN claimed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 US claimed
WO-2014141092-A2 IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR SHASUN PHARMACEUTICALS LIMITED (IN) 2014-09-18 WO claimed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 US claimed
EP-2480524-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF Cadila Healthcare Limited (IN) 2012-08-01 EP claimed
WO-2011039781-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-04-07 WO claimed
US-7354977-B1 Process for hydroxyalkylating carboxylic acid-functionalized materials HENKEL CORPORATION (US) 2008-04-08 US claimed
EP-0973721-A4 PROCESS FOR HYDROXYALKYLATING CARBOXYLIC ACID-FUNCTIONALIZED MATERIALS LOCTITE CORP (US) 2000-05-10 EP claimed
EP-0973721-A1 PROCESS FOR HYDROXYALKYLATING CARBOXYLIC ACID-FUNCTIONALIZED MATERIALS LOCTITE CORPORATION (US) 2000-01-26 EP claimed
WO-1998031655-A1 PROCESS FOR HYDROXYALKYLATING CARBOXYLIC ACID-FUNCTIONALIZED MATERIALS LOCTITE CORPORATION (US) 1998-07-23 WO claimed
US-5116888-A Addition-condensation copolymer THE GLIDDEN COMPANY (US) 1992-05-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA TDP1 1813/4885CYP3A4 737/4885ESR1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.